Linked Life Data

12874087

Source:http://linkedlifedata.com/resource/pubmed/id/12874087

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12874087rdf:typepubmed:Citationlld:pubmed
pubmed-article:12874087lifeskim:mentionsumls-concept:C0020538lld:lifeskim
pubmed-article:12874087lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:12874087lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:12874087lifeskim:mentionsumls-concept:C0014939lld:lifeskim
pubmed-article:12874087lifeskim:mentionsumls-concept:C1098320lld:lifeskim
pubmed-article:12874087lifeskim:mentionsumls-concept:C1412113lld:lifeskim
pubmed-article:12874087lifeskim:mentionsumls-concept:C1527148lld:lifeskim
pubmed-article:12874087lifeskim:mentionsumls-concept:C1555029lld:lifeskim
pubmed-article:12874087lifeskim:mentionsumls-concept:C0231491lld:lifeskim
pubmed-article:12874087pubmed:issue4lld:pubmed
pubmed-article:12874087pubmed:dateCreated2003-10-3lld:pubmed
pubmed-article:12874087pubmed:abstractTextThe influence of estrogen on the regulation of cardiovascular function remains a controversial and complex area of investigation. We assessed the effects of estrogen depletion in the congenic mRen(2). Lewis rat, established from the back-cross of the original (mRen2)-27 transgenic onto the Lewis inbred strain. Ovariectomy of heterozygous mRen(2). Lewis at 4 to 5 weeks resulted in a progressive increase in blood pressure compared with the sham surgery congenics at weeks 6 to 11. At 11 weeks, the ovariectomized mRen(2). Lewis (OVX) systolic blood pressure averaged 195+/-3.7 mm Hg versus 141+/-4.0 mm Hg for sham. Plasma Angiotensin (Ang) II, serum ACE activity, plasma renin concentration, as well as urinary excretion of Ang II, 8-isoprostane F2alpha, and endothelin-1 were elevated; however, renal mRNA levels of eNOS were suppressed after ovariectomy. Estrogen replacement reduced blood pressure below both the sham and OVX by 11 weeks (125+/-2.9 mm Hg, n=7, P<0.01 versus OVX and sham). Moreover, the AT1 receptor antagonist olmesartan (CS866; week 12 to 16) essentially normalized blood pressure to 113+/-5.4 mm Hg (n=6, P<0.01 versus OVX and sham). The attenuation of the hypertension was still evident 7 weeks after complete withdrawal of treatment (124+/-4.1 mm Hg at week 23). In summary, the OVX mRen.2. Lewis exhibited a rapid and sustained increase in blood pressure. Estrogen or olmesartan lowered pressure by a similar extent. We conclude that the ovary exerts considerable influence on the regulation of the blood pressure in the mRen2. Lewis strain, possibly by limiting activation of the renin-angiotensin system.lld:pubmed
pubmed-article:12874087pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12874087pubmed:languageenglld:pubmed
pubmed-article:12874087pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12874087pubmed:citationSubsetIMlld:pubmed
pubmed-article:12874087pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12874087pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12874087pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12874087pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12874087pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12874087pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12874087pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12874087pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12874087pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12874087pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12874087pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12874087pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12874087pubmed:statusMEDLINElld:pubmed
pubmed-article:12874087pubmed:monthOctlld:pubmed
pubmed-article:12874087pubmed:issn1524-4563lld:pubmed
pubmed-article:12874087pubmed:authorpubmed-author:FerrarioCarlo...lld:pubmed
pubmed-article:12874087pubmed:authorpubmed-author:BrosnihanK...lld:pubmed
pubmed-article:12874087pubmed:authorpubmed-author:GallagherPatr...lld:pubmed
pubmed-article:12874087pubmed:authorpubmed-author:AverillDavid...lld:pubmed
pubmed-article:12874087pubmed:authorpubmed-author:ChappellMark...lld:pubmed
pubmed-article:12874087pubmed:issnTypeElectroniclld:pubmed
pubmed-article:12874087pubmed:volume42lld:pubmed
pubmed-article:12874087pubmed:ownerNLMlld:pubmed
pubmed-article:12874087pubmed:authorsCompleteYlld:pubmed
pubmed-article:12874087pubmed:pagination781-6lld:pubmed
pubmed-article:12874087pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:12874087pubmed:meshHeadingpubmed-meshheading:12874087...lld:pubmed
pubmed-article:12874087pubmed:meshHeadingpubmed-meshheading:12874087...lld:pubmed
pubmed-article:12874087pubmed:meshHeadingpubmed-meshheading:12874087...lld:pubmed
pubmed-article:12874087pubmed:meshHeadingpubmed-meshheading:12874087...lld:pubmed
pubmed-article:12874087pubmed:meshHeadingpubmed-meshheading:12874087...lld:pubmed
pubmed-article:12874087pubmed:meshHeadingpubmed-meshheading:12874087...lld:pubmed
pubmed-article:12874087pubmed:meshHeadingpubmed-meshheading:12874087...lld:pubmed
pubmed-article:12874087pubmed:meshHeadingpubmed-meshheading:12874087...lld:pubmed
pubmed-article:12874087pubmed:meshHeadingpubmed-meshheading:12874087...lld:pubmed
pubmed-article:12874087pubmed:meshHeadingpubmed-meshheading:12874087...lld:pubmed
pubmed-article:12874087pubmed:meshHeadingpubmed-meshheading:12874087...lld:pubmed
pubmed-article:12874087pubmed:meshHeadingpubmed-meshheading:12874087...lld:pubmed
pubmed-article:12874087pubmed:meshHeadingpubmed-meshheading:12874087...lld:pubmed
pubmed-article:12874087pubmed:meshHeadingpubmed-meshheading:12874087...lld:pubmed
pubmed-article:12874087pubmed:meshHeadingpubmed-meshheading:12874087...lld:pubmed
pubmed-article:12874087pubmed:meshHeadingpubmed-meshheading:12874087...lld:pubmed
pubmed-article:12874087pubmed:meshHeadingpubmed-meshheading:12874087...lld:pubmed
pubmed-article:12874087pubmed:meshHeadingpubmed-meshheading:12874087...lld:pubmed
pubmed-article:12874087pubmed:meshHeadingpubmed-meshheading:12874087...lld:pubmed
pubmed-article:12874087pubmed:meshHeadingpubmed-meshheading:12874087...lld:pubmed
pubmed-article:12874087pubmed:meshHeadingpubmed-meshheading:12874087...lld:pubmed
pubmed-article:12874087pubmed:year2003lld:pubmed
pubmed-article:12874087pubmed:articleTitleEstrogen or the AT1 antagonist olmesartan reverses the development of profound hypertension in the congenic mRen2. Lewis rat.lld:pubmed
pubmed-article:12874087pubmed:affiliationHypertension and Vascular Disease Center, Wake Forest University Health Sciences, Medical Center Boulevard, Winston-Salem, NC 27157-1095, USA. mchappel@wfubmc.edulld:pubmed
pubmed-article:12874087pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12874087pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:12874087pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12874087lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12874087lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12874087lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12874087lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12874087lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12874087lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12874087lld:pubmed